Catalent Pharma Solutions

Catalent, UMN Pharma collaborate on biosimilar development, production in Japan

Monday, December 17, 2012 11:35 AM

Catalent Pharma Solutions, a Somerset, N.J.-based developer of solutions and drug delivery technology, has signed an agreement to provide UMN Pharma, a Japanese pharmaceutical company, a broad range of biosimilar cell lines using Catalent's proprietary GPEx technology.

More... »

Catalent Pharma launches Catalent Applied Drug Delivery Institute

Monday, October 22, 2012 11:38 AM

Catalent Pharma Solutions, a developer of solutions and advanced drug delivery technologies, has launched its Catalent Applied Drug Delivery Institute.

More... »

Catalent Pharma and CTC BIO to partner in South Korea

Monday, September 17, 2012 11:21 AM

Catalent Pharma Solutions, a Somerset, N.J.-based developer of solutions and drug delivery technology, and CTC Bio, a drug and service provider based in Seoul, South Korea, have entered into a collaboration to provide optimal solutions to South Korean pharmaceutical companies seeking to commercialize solid oral dose and controlled release products in the U.S. and Europe.

More... »

Catalent, Bend Research to provide integrated solutions for oral controlled-release technologies

Monday, June 25, 2012 10:17 AM

Catalent Pharma Solutions of Somerset, N.J., and Bend Research of Bend, Ore., have entered into an agreement to provide integrated solutions for pharmaceutical companies seeking to develop and manufacture specialized multiparticulate oral controlled-release products.

More... »

Frazier Healthcare acquires U.S. packaging operations from Catalent

Wednesday, June 20, 2012 03:26 PM

Somerset, N.J.-based Catalent Pharma Solutions has closed the purchase and sale of its U.S. commercial pharmaceutical packaging operations based in Philadelphia, Penn., and Woodstock, Ill., to Frazier Healthcare.

More... »

BASF and Catalent aim to solve bioavailability challenges

Friday, April 6, 2012 12:36 PM

Catalent Pharma Solutions, a services and solutions provider, and BASF, a leading chemical company, have formed an open alliance to provide solutions to overcome bioavailability challenges of new molecular entities with solubility or permeability challenges. 

More... »

Catalent acquires Aptuit’s Clinical Trial Supplies business

Tuesday, August 23, 2011 11:36 AM

Catalent Pharma Solutions has agreed to acquire the Clinical Trial Supplies business of Aptuit for cash consideration of $410 million on a cash and debt free basis. The acquisition will substantially expand Catalent's Development & Clinical Services business, transforming it into the #2 provider globally in clinical supply solutions, and adding important development and clinical manufacturing expertise and capacity. Following the close of the transaction, Aptuit will focus on its market-leading integrated discovery to mid-phase development business.

More... »